2103399-35-3

Basic information

• Product Name: (S)-5-fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride
• CAS NO: 2103399-35-3
• Molecular Weight: 187.644
• Mol File: 2103399-35-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S)-5-fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5-fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride(2103399-35-3)
• EPA Substance Registry System: (S)-5-fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride(2103399-35-3)

Safety Data

• Hazardous Substances Data: 2103399-35-3(Hazardous Substances Data)

Usage

General Description

The chemical (S)-5-fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride, also known as sibutramine hydrochloride, is a pharmaceutical compound that has been used as an appetite suppressant for the treatment of obesity. It functions as a serotonin-norepinephrine reuptake inhibitor (SNRI), leading to increased levels of these neurotransmitters in the brain, which in turn helps to reduce appetite and promote weight loss. However, due to concerns about its potential for cardiovascular side effects, sibutramine hydrochloride was withdrawn from the market in many countries. Its use is now restricted or banned in several jurisdictions.

Upstream product

• 700-84-5 5-fluoro-1-indanone 
• 101752-05-0 methanol hydrochloride 
• 148960-32-1 5-fluoro-1-indanone oxime 

Relevant articles and documents

CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.

alpha-SUBSTITUTED GLYCINAMIDE DERIVATIVE

The present invention is to provide a novel α-substituted glycinamide derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. The present invention provides a compound represented by the general formula (I), which has TRPM8 inhibitory effects: [wherein A1 represents a C6-10 aryl and the like, A2 represents a C6-10 aryl and the like, X represents CH and the like, Y represents —CR1R2— and the like, R1 and R2 independently represent a hydrogen atom and the like, R3 and R4 independently represent a halogen atom and the like, n is 1 or 2], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.

NOVEL TRPM8 INHIBITOR

PROBLEM TO BE SOLVED: To provide a novel α-substituted glycine amide derivative, or a pharmaceutical composition containing pharmacologically acceptable salt thereof, and a medicinal use thereof. SOLUTION: The present invention provides a compound expressed by a general formula (I) having TRPM8 inhibitory action (in the formula, A1 denotes C6-10 aryl or the like, A2 denotes C6-10 aryl or the like, X denotes CH or the like, Y denotes -CR1R2- or the like, R1 and R2 denote hydrogen atom or the like independently, R3 and R4 denote halogen atom or the like independently, and n denotes 1 or 2), or a pharmaceutical composition containing pharmacologically acceptable salt thereof. Furthermore, a pharmaceutical composition of the present invention is usable as treatment or a prophylactic drug of disease or symptom caused by hyperexcitement or disorder of afferent nerves. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT